Global Circulating Tumor Cells Prognostic Technologies Market US$ 2.3 Billion by 2021

Global Circulating Tumor Cells Prognostic Technologies Market US$ 2.3 Billion by 2021

Circulating tumor cells (CTCs) are cells that have shed into the vasculature or lymphatics from a primary tumor and are carried around the body in the circulation. Circulating tumor cells (can be detected in the circulation, where the detection of CTCs in blood can provide prognostic information. Advanced technologies emerge to characterize CTCs at the molecular level, where the biological information can be obtained in real time. There is a great potential of CTCs to be used as pharmacodynamic and predictive biomarkers and potentially their use in revealing drug resistance in real time.

Circulating Tumor Cells Prognostic Technologies Market 2017-2021 report estimates the global circulating tumor cells prognostic technologies market to reach nearly US$ 1.9 Billion in 2020, at a CAGR of 18.9% from 2017 to 2021 – iHealthcareAnalyst, Inc.

Visit the Circulating Tumor Cells Prognostic Technologies Market 2017-2021 report https://www.ihealthcareanalyst.com/report/circulating-tumor-cells-prognostic-technologies-market/

The global circulating tumor cells prognostic technologies market segmentation is based on technology tumor cell enrichment, centrifugation, filtration, immunological methods, tumor cell detection, molecular methods, optical methods), and its application (breast cancer, colorectal cancer, prostate cancer, lung cancer, ovarian cancer and pancreatic cancer, etc.) The global circulating tumor cells prognostic technologies market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global circulating tumor cells prognostic technologies market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

  1. Technology
    • Tumor Cell Enrichment
      • Centrifugation
      • Filtration
      • Immunological Methods
    • Tumor Cell Detection
      • Molecular Methods
      • Optical Methods
  1. Application
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others (Lung Cancer, Ovarian Cancer and Pancreatic Cancer, etc.)
  1. Geography (Region, Country)
    • North America (U.S., Canada)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World
  1. Company Profiles
    • AdnaGen GmbH
    • Advanced Cell Diagnostics, Inc.
    • AVIVA Biosciences Corporation
    • Celula, Inc.
    • Epic Sciences, Inc.
    • Fluxion Biosciences, Inc.
    • Rarecells USA, Inc.
    • Silicon Biosystems, S.p.A.
    • Vitatex, Inc.
    • Veridex, LLC

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: http://www.ihealthcareanalyst.com

 

2017-11-05T10:00:12+00:00 Categories: Press Releases|